Brandy Betz Articles

•   RSS Feed
• View Profile

Last 50 articles...

• 3 Obamacare Lessons From Medicaid Expansion
• Allergan Waits to Exhale
• What Will Obamacare Do to Medicare?
• Top Obamacare Questions Answered
• Isis: Big Pharma's Little Friend
• 3 Obamacare Stories You Missed This Week
• Obamacare Falls Into Place, and Health Insurers Rejoice
• Sizing Up One of Obamacare's Biggest Players
• 3 Health-Care Stories You Should Know
• Obamacare Is Changing Health Insurance Forever
• Why This Health Insurer Dropped Today
• 3 Health Care Stories You Probably Missed
• Is Your State Embracing Obamacare?
• Why Cardinal Health Dropped
• This Week's Health Care Reform Headlines
• Better Health, an iPhone App Away
• Old, Sick, and Poor: Health Care's Most Expensive Patients
• This Week in Health Reform
• Does This Change the Medicaid Expansion Game?
• Can Health Insurance Still Profit From Baby Boomers?
• Merck's HPV Growth Continues
• A Drug That's Ready to Lose
• Elan Not Keen on Royalty Pharma's $6.6 Billion Offer
• What's Next for Dynavax?
• Merck's Low Cholesterol
• Sanofi's GLP-1 Accepted for Review by FDA
• Will Isis Right Pfizer's Wrong?
• Merck's Weakest Blockbuster?
• Does the Arthritis Market Have Growing Pains?
• Merck's Dynamic Duo
• Why Regeneron Shares Dropped Today
• Why Seattle Genetics Dropped
• Merck's Crash of a Titan
• Takeover Rumors Surround This Drug Stock
• A Cholesterol-Treatment Contender Partners Up
• Sanofi's New Diabetes Play Moves Forward
• What's Ahead for Exelixis?
• Who Will Win This Small Drug Market?
• What's in Regeneron's Pipes?
• Statins Beware?
• A Late-Stage Threshold for Success?
• MAP Gets Inhaled by Allergan
• What's Next for Affymax?
• 3 Things to Watch at Alkermes
• What's Ahead for Ariad?
• JPMorgan Healthcare Conference Rewind: Rigel Pharmaceuticals
• BioMarin's Big Week
• Vertex: The Year Ahead
• 3 Health Care Companies I'm Watching Today
• AbbVie's Born -- What Now?